Appia Bio logo

Appia Bio

Collaborates across a diversity of disciplines, which is critical to developing next-generation therapies for patients

13 employees · est. 2020

VS
Thymmune Therapeutics logo

Thymmune Therapeutics

Biotech firm developing thymic cell therapies to restore immune function using machine learning

26 employees · est. 2019 · Cambridge, United States

Thymmune Therapeutics is the older company (2020 vs 2019).

Side-by-Side Comparison

Appia Bio Thymmune Therapeutics
Founded
2020 2019 older
Headquarters
Not tracked yet Cambridge, United States
Employees
13 26
Industry
Biotechnology, Health Care, Life Sciences Biotechnology, Health and Wellness
Funding Stage
Series A Seed
Total Funding
$52.00M $44.30M
Funding Rounds
2 3
Services
Not tracked yet Development of thymic cell engineering platform, Mass production of iPSC-derived thymic cells, Research and development of therapies for immune disorders, Preclinical studies of thymic cell therapy, Therapeutic development for healthy immune aging
Target Customers
Not tracked yet Patients with immune-mediated diseases, Individuals with immunodeficiencies, Patients experiencing age-related immune decline, Healthcare professionals seeking innovative treatments
Taxonomy
Cell Therapy, Allogeneic Cell Therapy, Engineered Cell Therapy, ACUA Technology Platform, CAR-iNKT Cells, Invariant Natural Killer T Cells, Hematopoietic Stem Cells, Lymphocyte Development, CAR Gene Engineering, TCR Gene Engineering, Chimeric Antigen Receptor, T-cell Receptor Thymic Cell Therapies, IPSC Manufacturing, Immunotherapy, Immune Restoration, Aging, Disease Treatment, Immunodeficiencies, Transplant Therapeutics, Autoimmune Diseases, Cell Engineering, Off-the-shelf Therapies, Therapeutic Pipeline, Biotech Innovation
Website
appiabio.com thymmune.com
Appia Bio logo

About Appia Bio

Appia Bio, an early-stage biotechnology company located in Los Angeles, California, was founded in 2020. The company's core focus is on creating and developing engineered allogeneic cell therapies that target a wide range of medical indications through its innovative and scalable platform, ACUA (App...

Thymmune Therapeutics logo

About Thymmune Therapeutics

Thymmune Therapeutics, a Cambridge, MA-based biotech firm, is pioneering in the realm of thymic cell therapies with an innovative use of machine learning to restore immune function. Founded in 2019, the company focuses on developing a unique platform that utilizes iPSC-thymic cell manufacturing to p...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at Appia Bio and Thymmune Therapeutics — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at Appia Bio and Thymmune Therapeutics — by email.

Frequently Asked Questions

Appia Bio — Collaborates across a diversity of disciplines, which is critical to developing next-generation therapies for patients. Thymmune Therapeutics — Biotech firm developing thymic cell therapies to restore immune function using machine learning. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Appia Bio has raised $52.00M while Thymmune Therapeutics has raised $44.30M.
Appia Bio and Thymmune Therapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Appia Bio with someone else

Start typing a company name or domain.

One analytics cookie (Google Analytics). Cookie Policy